Cereno Scientific’s innovative Phase II study design in PAH with CS1 is accepted for presentation at the CHEST annual meeting on Oct 16-19 in Nashville, US

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on clinical Phase II drug candidate CS1 has been accepted at the CHEST annual meeting 2022 hosted by the American College of Chest Physicians (CHEST) in Nashville, US, on October 16-19. The abstract has been selected for an oral presentation and is titled “An innovative Phase 2 clinical trial design for the assessment of CS1 – a novel therapy in the treatment of pulmonary arterial hypertension.” It will be presented by Dr. Raymond Benza, PI of Cereno’s Phase II study in PAH with CS1 and Professor and Director of the Division of Cardiovascular Diseases at the Ohio State University Wexner Medical Center.

“I am looking forward to the opportunities a presentation at CHEST brings, enabling us to continue to establish and build Cereno’s footprint in the medical community. After having all of our three R&D pipeline candidates accepted for presentations at various medical congresses in Europe this summer, the presentation in Nashville will further raise awareness about our exciting drug candidate CS1 and its potential as a new treatment for the orphan disease PAH. This time at a scientific conference in the US where also our ongoing Phase II study is being conducted,” said Sten R. Sörensen, CEO at Cereno.

The abstract titled “An innovative phase 2 clinical trial design for the assessment of CS1 – a novel therapy in the treatment of pulmonary arterial hypertension” was authored by Dr. Raymond Benza at Wexner Medical Center, Ohio State University; Dr. Niklas Bergh at Institute of Medicine, University of Gothenburg and Cereno; Dr. Philip Adamson at Abbott, and Dr. Björn Dahlöf at Institute of Medicine, University of Gothenburg and Cereno. The abstract has been selected to be presented as an oral presentation in the PAH Assessment, Treatment, and Outcomes Analyses session, by Dr. Raymond Benza.

The abstract will be published in an online supplement journal, CHEST®, following the annual meeting.

Drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is currently ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About the Phase II study with CS1 in PAH

CS1 was granted an orphan drug designation (ODD) for the treatment of the rare disease PAH by the US FDA in March 2020 and in September 2021, Cereno obtained FDA acceptance of an investigational new drug (IND) application allowing initiation of the Phase II study. This study intends to evaluate drug candidate CS1’s safety, tolerability, dose, and exploratory efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use Abbott’s cutting-edge technology CardioMEMS HF System in the study. There will be a 12-week drug treatment period and a two-week follow-up period. The primary endpoint is safety and tolerability. All standard efficacy endpoints for this patient group will be explored as well as validated risk scores before and after treatment. The study includes at least ten different clinical sites in the US and aim to include 30 patients with PAH. Further information is available at https://www.clinicaltrials.gov/ (ClinicalTrials.gov identifier NCT05224531).

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular disease. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-fibrotic, anti-inflammatory and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNOB). More information on www.cerenoscientific.com.